Baricitinib vs Ipilimumab

Baricitinib vs Ipilimumab: Overview

This comparison examines the pharmacological differences between Baricitinib and Ipilimumab.

Mechanism of Action

Baricitinib: Selective JAK1 and JAK2 inhibitor blocking cytokine signaling involved in inflammation.

Ipilimumab: Fully human anti-CTLA-4 IgG1 monoclonal antibody that blocks CTLA-4 inhibitory signaling.

Pharmacokinetics

Half-life: Baricitinib — 12 hours; Ipilimumab — 14.7 days.

Chemical Properties

Molecular Formula: Baricitinib — C16H17N7O2S.

Molecular Weight: Baricitinib — 371.4170 g/mol.

Type: Baricitinib — Small molecule; Ipilimumab — Antibody.